Scienture Holdings (SCNX) Raw Materials (2022 - 2023)
Scienture Holdings' (SCNX) quarterly Raw Materials came in at $1.9 million in Q3 2023, up 2669.12% quarter-over-quarter from $68448.0 in Q4 2022.
Analysis
Scienture Holdings (SCNX) Raw Materials (2022 - 2023) Analysis & Trends
Scienture Holdings has disclosed Raw Materials across 2 years of filings, most recently posting $1.9 million for Q3 2023.
- In Q3 2023, Raw Materials changed N/A year-over-year to $1.9 million; the TTM figure through Sep 2023 stood at $1.9 million (changed N/A YoY), while the FY2022 annual figure was $68448.0, changed N/A from the prior year.
- Raw Materials came in at $1.9 million for Q3 2023 at Scienture Holdings, up from $68448.0 in the prior quarter.
- In the past five years, Raw Materials ranged from a high of $1.9 million in Q3 2023 to a low of $68448.0 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | Scienture Holdings | 15.19 Mn | 15.19 Mn | 335,779.00 |